The drug, known as necitumumab, improved patients’ overall chances of survival, yet people taking the medicine also experienced more risk, Food and Drug Administration staff said in a report Tuesday.
After years of pipeline failures, Eli Lilly and Co. is on a bit of a hot streak. This month alone, the Indianapolis-based drugmaker has reported positive results from clinical trials of four experimental drugs.
Intarcia Therapeutics Inc. is betting its matchstick-size pump could take market share from Eli Lilly and Co., AstraZeneca Plc and Novo Nordisk A/S.
Axovant Sciences Ltd., a company without a finished product or a dime of sales, has an almost $3 billion valuation after its public-market debut. The IPO shows the staggering potential for any company that can develop a successful Alzheimer’s treatment.
Dr. Kent Brantly was awarded the Dr. Nathan Davis International Award in Medicine from the American Medical Association for his service in Liberia during last summer’s Ebola outbreak.
Indianapolis-based Eli Lilly and Co. plans to introduce its version of Sanofi’s Lantus insulin for diabetes in Europe in the third quarter, said Enrique Conterno, the president of Lilly Diabetes.
In a bid to get into the white-hot market for drugs that use the body’s immune system, Eli Lilly and Co. will spend $60 million to form a research partnership with Germany-based BioNTech.
New research from the Mayo Clinic is bringing back a long-running debate over whether drug companies like Eli Lilly and Biogen are focusing on the right target in developing therapies to treat the disease.
A proposal aimed at giving terminally ill patients in Indiana easier access to experimental drugs not yet on pharmacy shelve is about to become law.
The results of an experimental drug for Alzheimer’s disease provide the best evidence so far that the memory-robbing condition is caused by an errant protein in the brain. Drugmakers including Eli Lilly have been concentrating their Alzheimer’s research on that area.
Major drugmakers—including Indianapolis-based Eli Lilly and Co.—the British government and a top Alzheimer's research charity are pooling more than $100 million to create a global fund to accelerate efforts to find a treatment or cure.
An Indiana Senate committee is considering a bill that would give terminally ill patients easier access to experimental drugs that have not received full federal approval. Indiana is one of nearly two dozen states that are considering the legislation.
Paris-based drugmaker Sanofi had revenue of $8.4 billion from Lantus last year. It lost U.S. patent protection this month and will lose exclusive rights in Europe in May.
Although the experimental diabetes drug is in final-stage testing and showing promising results, Lilly wants to better understand its effect on liver fat.
While the tests will likely help drug companies like Eli Lilly and Co. evaluate medicines, they’ll also create wrenching personal and ethical dilemmas for patients who will have to live with the knowledge that they’re destined to develop the disease.
Indianapolis hospital leaders have spent the past two months ironing out a plan to deal with any cases of Ebola that emerge in Indiana. The plan is aimed at ensuring effective care while also minimizing the need to bring other hospital services to a virtual halt while patients are under care.
Eli Lilly and Co. would be a logical acquirer for the maker of a drug that could treat agitation in Alzheimer’s patients.
Gov. Mike Pence appeared on a webcast with health care workers Thursday to talk about Ebola and the state’s preparations should the disease arrive in the state.
Tabalumab was expected to generate about $250 million to $300 million a year in sales in several years.
Design can help thwart antibiotic-resistant bacteria
